The 5-year survival rate of metastatic melanoma is 31–34% with targeted combined BRAF–MEK inhibitor therapy, 42–43% with anti-PD1 inhibitor therapy, and 46–57% with combined anti-CTLA-4 and anti-PD-1 therapy [14,15,16]. The gene discussed is CTLA4; the disease is metastatic melanoma.